WO2022012635A9 - 一种药物组合物及其用途 - Google Patents

一种药物组合物及其用途 Download PDF

Info

Publication number
WO2022012635A9
WO2022012635A9 PCT/CN2021/106558 CN2021106558W WO2022012635A9 WO 2022012635 A9 WO2022012635 A9 WO 2022012635A9 CN 2021106558 W CN2021106558 W CN 2021106558W WO 2022012635 A9 WO2022012635 A9 WO 2022012635A9
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
bicyclol
ginsenoside monomer
tumor
treating
Prior art date
Application number
PCT/CN2021/106558
Other languages
English (en)
French (fr)
Other versions
WO2022012635A1 (zh
Inventor
范代娣
殷诗玉
段志广
严建亚
Original Assignee
陕西巨子生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陕西巨子生物技术有限公司 filed Critical 陕西巨子生物技术有限公司
Priority to AU2021310228A priority Critical patent/AU2021310228B2/en
Publication of WO2022012635A1 publication Critical patent/WO2022012635A1/zh
Publication of WO2022012635A9 publication Critical patent/WO2022012635A9/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种药物组合物，所述药物组合物包括：人参皂苷单体和双环醇。所述药物组合物对肝癌的化学预防和治疗具有显著疗效，相比于与单独使用人参皂苷单体或单独使用双环醇，具有显著的协同和增效作用。人参皂苷单体和双环醇在制备预防和／或治疗肿瘤的药物组合物中的用途，以及人参皂苷单体在促进预防和／或治疗肿瘤的药物组合物的作用中的用途。
PCT/CN2021/106558 2020-07-17 2021-07-15 一种药物组合物及其用途 WO2022012635A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021310228A AU2021310228B2 (en) 2020-07-17 2021-07-15 Pharmaceutical composition and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010693107.4 2020-07-17
CN202010693107.4A CN111759853B (zh) 2020-07-17 2020-07-17 一种药物组合物及其用途

Publications (2)

Publication Number Publication Date
WO2022012635A1 WO2022012635A1 (zh) 2022-01-20
WO2022012635A9 true WO2022012635A9 (zh) 2023-01-05

Family

ID=72728460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/106558 WO2022012635A1 (zh) 2020-07-17 2021-07-15 一种药物组合物及其用途

Country Status (3)

Country Link
CN (1) CN111759853B (zh)
AU (1) AU2021310228B2 (zh)
WO (1) WO2022012635A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111759853B (zh) * 2020-07-17 2021-10-22 陕西巨子生物技术有限公司 一种药物组合物及其用途
EP4101438A1 (en) * 2021-06-11 2022-12-14 RainCastle bio. Limited Combination treatment of a saponin agent and an anthelminitic agent against cancer
CN115088833A (zh) * 2022-05-20 2022-09-23 唛迪森营养科技(江苏)有限公司 一种用于预防和/或治疗肿瘤患者肠道损伤的功能性食品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100423727C (zh) * 2006-01-19 2008-10-08 云南天秀植物科技开发有限公司 一种抗肿瘤的药物组合物及其制备工艺
CN100444865C (zh) * 2006-07-06 2008-12-24 陈红亮 含有双环醇的协同药用组合物
CN104825531A (zh) * 2015-05-29 2015-08-12 中国药科大学 一种具有抗肝损伤活性的药物组合物及其应用
CN206120771U (zh) * 2015-06-03 2017-04-26 南京三迭纪医药科技有限公司 药品剂型
WO2017123056A1 (ko) * 2016-01-14 2017-07-20 경희대학교 산학협력단 나노 약물전달체; 및 인삼추출물 또는 이로부터 분리된 진세노사이드를 포함하는 나노 복합체
CN106727638A (zh) * 2016-12-28 2017-05-31 吉林大学 人参皂苷作为乙酰肝素酶抑制剂在制备肿瘤治疗药物中的应用
CN109106711A (zh) * 2017-06-23 2019-01-01 北京协和药厂 双环醇及其可药用衍生物用于预防或治疗药物性肝损伤的用途
KR102085115B1 (ko) * 2017-07-21 2020-03-05 스노우화이트팩토리(주) 마그헤마이트-사포닌 나노결합체를 유효성분으로 함유하는 조혈기능 장애 질환 예방 또는 치료용 약학조성물
CN110090236B (zh) * 2018-01-29 2022-09-16 吉林海颐康达生物科技发展有限公司 药物组合物及其用途
CN108815218B (zh) * 2018-06-29 2021-05-04 吉林大学 药物组合物及其用途
CN111285909A (zh) * 2018-12-06 2020-06-16 中国医学科学院药物研究所 光学活性双环醇葡萄糖苷及其制备方法和防治肝病的应用
CN109793711A (zh) * 2019-03-01 2019-05-24 淮阴师范学院 一种肝癌靶向载人参皂苷ck壳聚糖聚合物胶束递药系统及其制备方法
CN111759853B (zh) * 2020-07-17 2021-10-22 陕西巨子生物技术有限公司 一种药物组合物及其用途

Also Published As

Publication number Publication date
CN111759853A (zh) 2020-10-13
AU2021310228A1 (en) 2023-03-02
WO2022012635A1 (zh) 2022-01-20
CN111759853B (zh) 2021-10-22
AU2021310228B2 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
WO2022012635A9 (zh) 一种药物组合物及其用途
WO2019220369A3 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
EP3953379A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING MODIFIED TET2 T LYMPHOCYTE CELL THERAPY
WO2007084670A3 (en) Specific therapy using integrin ligands for treating cancer
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2009010287A3 (en) Specific therapy and medicament using integrin ligands for treating cancer
EP1971338B8 (en) Combination of zd6474 and pemetrexed
HUP0303927A2 (hu) Anti-angiogén ágensek és TNF-alfa alkalmazása kombinációs kezelésre
ZA202304965B (en) Combination therapy for treating cancer
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
WO2015035410A8 (en) Cancer therapy
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2023010512A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia.
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
EP3865141A4 (en) ANTI-CANCER AGENT, PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND KIT
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21841924

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021310228

Country of ref document: AU

Date of ref document: 20210715

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 21841924

Country of ref document: EP

Kind code of ref document: A1